C4 Therapeutics Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, C4 Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $12.86. The average 1-year stock price forecast is 320.26% higher than the current stock price, while the lowest is $7.00 (+128.76%) and the highest is $30 (+880.39%).

Price Target: $12.86 (+320.26%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$7.00	$12.86	$10	$30
Change	+128.76%	+320.26%	+226.80%	+880.39%

Analyst Ratings

The average analyst rating for C4 Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Apr '26	May '26	Jun '26	Aug '26	Sep '26	Oct '26
Strong Buy	7	7	6	6	6	6
Buy	1	1	1	1	1	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	7	7	7	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Unknown Analyst Guggenheim No rating	Guggenheim	Buy Initiates $7	Buy	Initiates	$7	+128.76%	Oct 22, 2026
Anupam Rama J.P. Morgan	J.P. Morgan	Buy Initiates $10	Buy	Initiates	$10	+226.80%	Oct 9, 2026
Derek Archila Wells Fargo	Wells Fargo	Buy Reiterates $10	Buy	Reiterates	$10	+226.80%	Aug 12, 2026
Etzer Darout Barclays	Barclays	Buy Maintains $7	Buy	Maintains	$7	+128.76%	Aug 12, 2026
Tyler Van Buren TD Cowen	TD Cowen	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Aug 12, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

26.40M

from 35.95M

-26.56%

from 35.95M

Revenue Next Year

22.29M

from 26.40M

-15.58%

from 26.40M

EPS This Year

-0.86

from -1.14

EPS Next Year

-0.96

from -0.86

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	45.79M	31.10M	20.76M	35.58M	35.95M	26.40M
Revenue Growth	37.93%	-32.08%	-33.25%	71.44%	1.02%	-26.56%
Operating Income	-82.13M	-129.53M	-139.03M	-117.18M	-104.49M	-125.47M
Net Income	-83.89M	-128.18M	-132.49M	-105.32M	-104.99M	-113.10M
EPS	-	-	-	-	-1.14	-0.86
Free Cash Flow	-	-	-	-	-99.30M	-100.00M
No. Analysts	-	-	-	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	43.0M
Avg	26.4M
Low	13.0M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	19.6%
Avg	-26.6%
Low	-63.8%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.74
Avg	-0.86
Low	-0.96

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-